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Immunotherapy is the only available treatment for metastatic renal cell cancer (RCC), but the response rate is only about 20% and
the treatment is occasionally associated with severe adverse effects. Thus, the selection of patients with a high susceptibility to
immunotherapy is needed; however, there is no promising molecular marker that can predict the response to immunotherapy for
RCC. This study was carried out to elucidate the potential role of apoptosis-related molecules Bcl-2 and Fas, as well as apoptotic and
proliferating indexes (AI, PI) as predictors of the susceptibility of metastatic RCC to immunotherapy. Immunohistochemical
examination of tumour tissues from 40 patients with metastatic RCC undergoing postoperative immunotherapy after radical
nephrectomy was performed. Patients with progressive disease (PD) after immunotherapy presented with decreased survival
(P¼0.006). Progressive disease correlated with higher PI in the primary lesion (P¼0.0087). All primary tumours of CR or PR patients
were negative for Bcl-2, whereas among NCþPD patients, 40.6% were positive for Bcl-2 (P¼0.0373). Patients in whom the primary
tumours were both Bcl-2- and Fas-negative showed significantly better responses to immunotherapy in comparison with the
remaining group (P¼0.0022). The Bcl-2 and Fas status of the primary lesion may become useful criteria for the selection of patients
with metastatic RCC for immunotherapy.
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Metastatic renal cell cancer (RCC) generally has a fatal outcome,
despite conventional chemotherapy, radiotherapy and hormonal
therapy. However, immunotherapy, such as the administration of
interferons (IFNs) or interleukin-2 (IL-2) has shown promise,
although the efficacy varies among cases and the total response
rate is approximately 20%. Immunotherapy should be performed
only in selected responders, because the treatment is sometimes
accompanied by severe adverse effects. Patients with a good
performance status (Atkins et al, 1993; Fyfe et al, 1995), prior
nephrectomy (Atkins et al, 1993; Fyfe et al, 1995; Figlin et al, 1997;
Rosenberg et al, 1998), metastases predominantly located in the
lung (Atkins et al, 1993; Fyfe et al, 1995; Rosenberg et al, 1998) and
only one site of metastatic disease (Negrier et al, 1998), with a clear
cell histological variant (Wu et al, 1998) are more likely to exhibit a
favourable response to immunotherapy. To date, however, no
reliable molecular markers have been identified that can predict
susceptibility to immunotherapy.
However, the mechanisms of RCC resistance to immunotherapy
are not well defined. Some in vitro studies have shown that Fas
(CD95/Apo1) promotes apoptosis in renal carcinoma cells by
immune cells and Bcl-2 prevents it. Previously, we demonstrated
the sensitisation of RCC cells to Fas-mediated apoptosis by IFN-g
(Tomita et al, 1996a) in vitro. This effect was attributed to the
regulation of downstream caspases (Tomita et al, 2003). Cytokines,
including IFNs, upregulate Fas in RCC cells (Nonomura et al,
1996), and thus increase the susceptibility to Fas-mediated
apoptosis. In RCC cell lines, Bcl-2 reduction has been shown to
be associated with increased sensitivity to anti-Fas (Hara et al,
2001). We found that Fas remarkably induced apoptosis in cells
with low Bcl-2 levels compared with high Bcl-2 expressors (Tomita
et al, 1996a). Furthermore, it has been recently shown that the
downregulation of Bcl-2 sensitises IFN-resistant renal cancer cells
to Fas (Kelly et al, 2004). Based on these studies, we considered
that Bcl-2 may be associated with the resistance of RCC to
immunotherapy in vivo.
Since 1987, we have accumulated specimens from about 500
RCC patients and followed their clinical course. We previously
investigated several apoptotic factors, together with their signalling
mechanism and reported the prognostic value of serum soluble Fas
in RCC patients (Kimura et al, 1999). Furthermore, the frequent
expression of Bcl-2 and the absence of p53 gene alterations were
found in these RCC specimens (Tomita et al, 1996b). Most
recently, we reported the relationship between Bcl-2 expression
and good prognosis in RCC patients and demonstrated a
significant difference in survival between Bcl-2-positive and
-negative patients without metastasis (Itoi et al,2 0 0 4 ) .N e v e r t h e l e s s ,
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sthe role of Bcl-2 appeared to be equivocal in patients with
metastatic disease. Thus, our interest focused on the detailed
clinical course, including response to immunotherapy in
addition to the expression of apoptosis-associated molecules
Bcl-2 and Fas, Ki-67 cell proliferation activity, TUNEL apoptotic
index in metastatic RCC, which remains not a rare clinical
problem despite recent advances in diagnostic modalities and
techniques.
We found that patients with metastatic RCC whose primary
tumours were both Bcl-2- and Fas-negative demonstrated a better
response to immunotherapy in clinical settings.
MATERIALS AND METHODS
Patients
Forty patients (35 men and five women) who underwent radical
nephrectomy for RCC between 1991 and 2001 at our institution
and presented with metastasis at the time of operation were
recruited in this study (Table 1). Experiments were carried out
with approval from the University’s Ethical Committee. The
histological diagnosis, grading and staging of the tumours were
determined according to UICC TNM classification. Following
nephrectomy, all patients were subjected to immunotherapy,
including treatment with IFN-a, IFN-g and/or IL-2, and some
patients received combined treatment with low-dose anticancer
drugs, 5-fluouracil or tegafur uracil, as presented in Table 1. The
mean follow-up period was 39 months (range 2–150). We
evaluated the response to immunotherapy according to the
General Rule for Clinical And Pathological Studies on Renal Cell
Carcinoma (April 1999, The 3rd Edition) published by the
Japanese Urological Association, Japanese Society of Pathology
and Japanese Radiological Society.
Immunohistochemistry
Avidin–biotin immunoperoxidase staining of fresh-frozen tissue
sections (5mm) of primary tumours in 28 cases and both primary
and metastatic sites in 12 cases was performed as described
previously (Tomita et al, 1993). The following primary monoclonal
antibodies were used – anti-Bcl-2 clone 124 (1/100 dilution, Dako,
Glostrup, Denmark), anti-Fas clone UB-2 (1/100 dilution, Medical
Bioscience Laboratory, Nagoya, Japan) and anti-human Ki-67
antigen clone MIB-1 (1/100 dilution, Dako). The specificity of each
antibody to Bcl-2 and Fas had been confirmed previously (Itoi
et al, 2004; Yamana et al, 2005). Negative controls were prepared
by omission of the primary monoclonal antibodies.
Evaluation of immunostaining
The staining results were evaluated independently by two
observers, neither of whom had prior knowledge of the clinical
or pathological data. There were no inter- and intra-sample
fluctuations in terms of staining intensity. Immunoreactivity for
Bcl-2 and Fas was graded according to the criteria as follows:
strong, more than 50% positively stained tumour cells; moderate,
10–50%; weak, less than 10%; negative, no positive tumour cells
in all fields. Tumour specimens showing weak staining were
considered negative. Those with moderate and strong staining
were considered positive. The proliferation index (PI) was
expressed as the percentage of Ki-67-positive cells among the
tumour cells, with at least 1000 cells counted in several fields for
each section, as reported previously (Itoi et al, 2004).
Detection of apoptosis
For TUNEL staining, an In Situ Cell Death Detection Kit (Takara,
Japan) was used according to the manufacturer’s instructions.
Cells were considered TUNEL-positive when brown reactivity was
detected in the nuclei. The apoptosis index (AI) was expressed as
the percentage of TUNEL-positive cells among the tumour cells,
with at least 1000 cells counted in several fields for each section, as
reported previously (Itoi et al, 2004).
Statistical analysis
Statistical analysis was performed using StatView 5.0 for
Macintosh (Abacus Concepts, Berkeley, CA, USA). The w
2 and
Fisher’s exact test were used to assess the correlation between the
expression and clinicopathological parameters. The Kaplan–Meier
method was used to determine survival, and the log-rank test was
used to compare curves. P-values less than 0.05 were considered
statistically significant.
RESULTS
Clinical course of the patients
Among 40 patients, a clinical response was observed in eight
patients (20.0%) (Figure 1 and Table 2) among which three showed
a complete response (CR) and five showed a partial response (PR).
The metastasis sites in responders were as follows: lung in four,
and one each in the following sites: brain and lung (which was
removed surgically before the start of immunotherapy and the
patient subsequently achieved CR), bone and lung (as above), liver
only, and lung and mediastinal lymph nodes (Figure 1). Complete
responses and/or PRs continued from 2 to 49 months. The
presence of metastases in just the lung vs other locations correlated
with longer survival (P¼0.0333).
Patients with progressive disease (PD) presented with decreased
disease-specific survival (P¼0.006) (Figure 2E); however, no
difference in survival was detected between the responders
Table 1 Patient characteristics
(%)
Mean age (range) years 59.4 (37–83)
Male/female 35/5
T stage
T1 7 17.5
T2 5 12.5
T3 23 57.5
T4 5 12.5
Grade
1 9 22.5
2 26 65.0
3 5 12.5
Histological type
Clear cell 38 95.0
Papillary 2 5.0
Metastatic site
Lung (lung mets only) 30 (18)
Other site 22
Treatment
IFN-a 15 37.5
IFN-a+5FU 5 12.5
IFN-g 8 20.0
IL-2 4 10.0
IL-2+IFN-a+TU 8 20.0
5FU¼5-fluorouracil; IFN¼interferon; IL¼interleukin; TU¼tegafur uracil.
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s(CRþPR) and the non-responders (NCþPD) (P¼0.0657)
(Figure 2E).
Expression of Bcl-2
Bcl-2 was detected in the cytoplasm of cancer cells (Figure 3A).
Bcl-2 was expressed in 13 of 40 (32.5%) primary specimens and
two of 12 (16.7%) metastatic lesions. Bcl-2 expression was not
related to the T stage or the tumour grade (Table 3). Bcl-2 staining
was positive in 13 of 32 (40.6%) primary tumours from patients
with no response (NCþPD) to immunotherapy and in 0 (0%) of
eight responders (CRþPR) (P¼0.0373) (Tables 2, 3). In addition,
four of the five responders examined were negative for Bcl-2 at
metastatic sites (Table 2). In this series of patients, there was no
correlation between Bcl-2 expression and disease-specific survival
(Figure 2A). In Bcl-2-negative cases, responders to immunother-
apy showed a better prognosis than non-responders (P¼0.0575)
(Figure 2B). Nevertheless, there was no difference in the disease-
specific survival between responders and non-responders. The
expression of Bcl-2 was not correlated to Fas; however, Fas
expression was significantly higher in the selected group of Bcl-
2( ) non-responders (91.7%) than responders (8.3%) (P¼0.0433).
Expression of Fas
Fas was detectable on the cell membranes and within the
cytoplasm of cancer cells (Figure 3B). It was expressed in 15 of
40 (37.5%) primary specimens and three of 12 (25%) metastatic
lesions. Fas expression was not related to the T stage or the tumour
grade (Table 3). Although there was no correlation between
responders to immunotherapy (CRþPR) and Fas expression,
patients with PD after immunotherapy expressed Fas more
frequently in primary tumours than other patients (CRþPRþNC)
(P¼0.0484) (Table 3). Among the eight responders, only one
primary tumour expressed Fas, and all five metastatic tumours
available from responders were negative for Fas, including a
metastatic tumour from a patient with positive Fas on the primary
RCC (Table 2). The disease-specific survival of patients char-
acterised according to Fas staining was not different (Figure 2C);
responders in the Fas( ) group tended to have longer survival,
although it was not statistically significant (Figure 2D). Both the
Bcl-2- and Fas-negative status correlated with the response
(CRþPR) to immunotherapy (P¼0.0022) (Table 4), although
this had no effect on survival (Figure 2F).
Detection of cell proliferation and apoptosis
Ki-67 was expressed in the nuclei of cancer cells (Figure 3C).
Proliferation index ranged from 0.66 to 20.52% (mean 5.28%).
Proliferation index was significantly higher in G3 than G1-2
(P¼0.0287) and Bcl-2-negative vs -positive cases (P¼0.0390)
(Table 5). Although there was no correlation between PI and
response to immunotherapy (CRþPR), higher PI correlated with
decreased survival (P¼0.0189) and patients with PD presented
with significantly higher PI in the primary tumour (P¼0.0087).
Figure 1 (A) Patient No. 8 chest CT shows mediastinal lymph nodes at
diagnosis (arrrowheads). (B) Mediastinal lymph node swelling disappeared
after immunotherapy (CR).
Table 2 Characteristics of responders to immunotherapy
Expression
a
No. Age Sex T N G
Histological
type
Metastatic
site Bcl-2 Fas Treatment
Best response
(duration, mos)
Follow up
(mos)
Status at last
follow-up
1 56 M 3b 0 1 Clear cell Lung  /   /  IL-2 PR (3) 14 DOD
2 37 M 3a 1 2 Clear cell Lung  /+  /  IL-2 PR (9) 50 DOD
3 61 M 1a 0 1 Clear cell Lung  /   /  IFN-a +5FU PR (7) 106 AWD
4 68 M 3a 0 2 Clear cell Lung  /  +/  IL-2 PR (10) 125 NED
b
5 66 F 1b 0 2 Clear cell Lung  /   /  IFN-a + (5FU-TU) PR (49) 100 AWD
6 54 M 3a 0 3 Papillary Liver  /NA  /NA IFN-a PR (2) 2 DOC
7 53 M 3a 0 2 Clear cell Lung  /NA  /NA IFN-a CR (33) 62 DOD
8 62 F 3b 2 3 Clear cell Lung, LN  /NA  /NA IL-2+IFN-a+TU CR (28) 30 NED
AWD¼alive with disease; CR¼complete response; DOC¼died of other causes; DOD¼died of disease; 5FU¼5-fluorouracil; IFN¼interferon; IL¼interleukin;
LN¼mediastinal lymph node; mos¼months; NA¼not available; NED¼no evidence of disease; PR¼partial response; TU¼tegafur uracil.
aExpression of primary site/
metastatic site.
bNo evidence of disease after resection of lung metastasis.
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clinicopathological parameter correlated with AI.
DISCUSSION
It is feasible that Bcl-2 represses immunotherapy-induced
apoptosis in RCC cells, as all primary tumours from responders
to immunotherapy were negative for Bcl-2 in this study; however, a
clinical response was observed in only eight of 27 (29.6%) Bcl-2-
negative cases. Therefore, we subclassified RCC patients into three
groups according to the Bcl-2 status and the response to
immunotherapy: negative Bcl-2 expression and good response to
immunotherapy, negative Bcl-2 expression and no response to
immunotherapy, and positive Bcl-2 expression (all non-respon-
ders). Bcl-2-positive cancers presented with lower PI determined
with Ki-67 (P¼0.039) (Table 5), which can explain the better
prognosis in non-metastatic cases reported previously (Itoi et al,
2004). Bcl-2 has been found to delay entry into the cell cycle and
repress cell proliferation in addition to its antiapoptotic action
(Linette et al, 1996; Mazel et al, 1996; O’Reilly et al, 1996).
Furthermore, the antiproliferative effect of Bcl-2 is separate from
the antiapoptotic effect (Uhlmann et al, 1996; Huang et al, 1997),
and became undetectable, whereas antiapoptotic activity persists
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Figure 2 (A) Disease-specific survival of all cases according to Bcl-2 expression. (B) Disease-specific survival in Bcl-2-negative cases only according to the
response to immunotherapy. (C) Disease-specific survival of all cases according to Fas expression. (D) Disease-specific survival in Fas-negative cases only
according to the response to immunotherapy. (E) Comparison of disease-specific survival between CRþPR vs NCþPD. (F) Comparison of disease-
specific survival between Bcl-2 and Fas-negative cases in CRþPR vs others.
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correlation between the Bcl-2 expression and prognosis in this
study (Figure 2A). This can be explained by the fact that all
patients in this group had metastasis at the time of surgery.
Moreover, the cancer cells in this study were challenged with
exposure to immune attack, which should presumably induce
apoptosis. In this setting, the presence of Bcl-2 prevented
apoptosis and ultimately shortened patient survival. So far, Bcl-
2( ) responders have showed better survival (Figure 2B), con-
firming this hypothesis.
We propose the following model based on these findings.
During the initial proliferative process, Bcl-2-positive tumour cells
have both antiapoptotic and antiproliferative activity. As the
disease progresses, antiproliferative activity is overcome by the
activation of multiple tumour-specific intracellular pathways,
whereas the antiapoptotic effect persists and renders tumour cells
resistant to apoptosis by immune cell attack. In contrast, Bcl-2-
negative tumours are sensitive to immunotherapy-triggered
apoptosis. We hypothesised that Bcl-2-negative tumour cells
with higher proliferative activity, as demonstrated by Ki-67, may
overcome the apoptotic effect of immune cells in this case.
Figure 3 Immunohistochemical staining of (A) Bcl-2 (No. 300), (B) Fas
(No.84), (C) Ki-67 (No. 242). Scale bars represent 100mm.
Table 3 Correlation of Bcl-2 and Fas expression with stage, grade or
response to immunotherapy
No. of Bcl-2 (+)(%) P-valueNo. of Fas (+)(%) P-value
T stage
T1 (n¼7) 1 14.3
NS
4 57.1
NS T2 (n¼5) 4 80.0 1 20.0
T3 (n¼23) 8 34.8 9 39.1
T4 (n¼5) 0 0 1 20.0
Grade
G1 (n¼9) 5 55.6
NS
3 33.3
NS G2 (n¼26) 8 30.8 9 34.6
G3 (n¼5) 0 0 3 60.0
Best response
CR (n¼3) 0 0
0.0373
00
0.0484 PR (n¼5) 0 0 1 20.0
NC (n¼12) 7 58.3 3 25.0
PD (n¼20) 6 30.0 11 55.0
CR¼complete response; NS¼not significant; PD¼progressive disease; PR¼partial
response; NC¼no changes.
3
5
3
5
#  
 
 
 
#
 
Table 4 Correlation of Bcl-2 and Fas expression with response to
immunotherapy
Response (%)
CR or PR NC or PD P-value
Bcl-2( ) and Fas( )( n¼15) 7 (46.7) 8 (53.3) 0.0022
Bcl-2(+) and/or Fas(+) (n¼25) 1 (4.0) 24 (96.0)
CR¼complete response; PD¼progressive disease; PR¼partial response; NC¼no
changes.
Table 5 Correlation of AI and PI with stage, grade, response to
immunotherapy and expression of Bcl-2 and Fas
AI (%, mean7s.d.) P-value PI (%, mean7s.d.) P-value
T stage
T1,2 0.675 (70.693) NS 5.002 (73.189) NS
T3,4 0.511 (70.558) 5.403 (74.316)
Grade
G1,2 0.603 (70.625) NS 4.629 (73.179) 0.0287
G3 0.260 (70.174) 9.858 (76.184)
Response
CR+PR 0.380 (70.281) NS 6.635 (76.127) NS
NC+PD 0.605 (70.648) 4.945 (73.288)
Bcl-2(+) 0.774 (70.942) NS 3.978 (73.865) 0.0390
Bcl-2( ) 0.457 (70.303) 5.911 (73.943)
Fas(+) 0.626 (70.667) NS 5.442 (72.796) NS
Fas( ) 0.524 (70.562) 5.187 (74.593)
AI¼apoptosis index; CR¼complete response; NS¼not significant; PD¼progres-
sive disease; PI¼proliferation index; PR¼partial response; s.d.¼standard deviation;
NC¼no changes.
Bcl-2 and Fas as a marker of response to immunotherapy in RCC
R Maruyama et al
1248
British Journal of Cancer (2006) 95(9), 1244–1249 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sAlthough PI was not significantly higher in Bcl-2( ) responders vs
non-responders, PI was significantly higher in PD patients after
immunotherapy than others (P¼0.0087). Thus, patients with high
PIs are considered inappropriate candidates for immunotherapy,
although a low PI does not necessarily guarantee a clinical
response.
In the Bcl-2( ) non-responders subgroup, other factors can
oppose apoptosis. Fas, the main target of cytotoxic immune cells,
and the Fas pathway status may be responsible for such
distinction. Although the expression of Bcl-2 was not correlated
to Fas, Fas expression was significantly higher in the non-
responders group Bcl-2( ) than responders (P¼0.0433). Further-
more, PD patients with immunotherapy expressed Fas more
frequently than others (CRþPRþNC) (P¼0.0484) (Table 3).
These findings conflict with the generally accepted view that Fas
mediates immune cell-triggered apoptosis; however, Fas stimula-
tion can be antagonised by the expression of non-functional Fas
splicing variants, Decoy receptor 3, the presence of soluble Fas, by
Fas gene mutations, or by the expression of downstream
inhibitors, such as XIAP or Bcl-2. Renal cell cancer has been
reported to harbour mutations in exons 7 and 9 of the Fas gene
(Takayama et al, 2002). Indeed, we have previously demonstrated
that RCC patients have elevated levels of soluble Fas, which was an
independent negative prognostic factor (Kimura et al, 1999). In
addition to inducing apoptosis, Fas can also promote cell growth
or differentiation (Mapara et al, 1993; Owen-Schaub et al, 1994;
Budd, 2002). From this point of view, it can be explained why
Bcl-2-negative and Fas-negative patients had a better response to
immunotherapy in metastatic RCC.
Bcl-2 and Fas can become useful predictive markers for
response to immunotherapy in metastatic RCC patients in clinical
settings, and PI can be an additional factor to predict the response
to immunotherapy. Although larger trials are necessary, the results
of this pilot study suggest that patients with Bcl-2-negative and
Fas-negative RCC could be appropriate candidates for immuno-
therapy.
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